Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021)
Century Therapeutics (IPSC) reported Preferred Stock Liabilities of $159.6 million for Q1 2021, up 357.1% quarter-over-quarter from $34.9 million in Q4 2020.
Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Century Therapeutics (IPSC) has 2 years of Preferred Stock Liabilities data on file, last reported at $159.6 million in Q1 2021.
- Preferred Stock Liabilities for Q1 2021 came in at $159.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $159.6 million (changed N/A YoY), and the FY2020 annual result was $34.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $159.6 million in Q1 2021 per IPSC's latest filing, from $34.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $159.6 million in Q1 2021 and troughed at $34.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Century Therapeutics | 444.99 Mn | 444.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 159.63 Mn |
| Dec 31, 2020 | 34.92 Mn |
| Sep 30, 2020 | 34.99 Mn |
| Jun 30, 2020 | 34.99 Mn |